ArticleMaterials today. Bio2025
Nano-adjuvant based on lipo-imiquimod self-assembly for enhanced foot-and-mouth disease virus vaccine immune responses
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Immunostimulant-integrated acrylate nanocomposite adjuvants potentiate foot-and-mouth disease vaccine efficacy.International journal of pharmaceutics: X · 2026Article
- Advancements in nanomaterial-based adjuvants for animal vaccines.Materials today. Bio · 2026Article
- Accidental intravitreal injection of a veterinary inactivated FMD vaccine resulting in noninfectious intraocular inflammation: a case report.Frontiers in medicine · 2026Article
- Performance of Imidazoquinoline Glycoconjugate BAIT628 as a TLR7 Agonist Prodrug for Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Systemic IFN-I Synergizes with Topical TLR7/8 Agonists to Suppress Metastatic Tumors.Research (Washington, D.C.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Excellent adjuvants and proper immunization routes play pivotal roles in activating a robust immune response. Nano-adjuvants have the advantages of enhancing immunogenicity, targeting delivery, and improving stability to provide a new solution for vaccine delivery. In this work, we designed and synthesized a pro-immunostimulant of liposolubility imiquimod derivative IMQP, which was synthesized by reaction of palmitoyl chloride with parent imiquimod (IMQ). Using an inactivated foot-and-mouth disease virus (FMDV) as antigen, and the as-synthesized IMQP containing long carbon chain as nano-adjuvant, we formulated a self-assembled foot-and-mouth disease nano-vaccine (IMQP@FMDV) by re-precipitation method for intradermal (I.D.) immunity vaccination. Because of its small size (∼131.75 ± 41.70 nm) and fat-soluble, the as-fabricated lipid nanoparticles (LNPs) showed promising potential for efficient delivery of antigens to immune cells. Also, lysosomal escape was confirmed by co-localization dendritic cells (DCs). Our findings demonstrated that IMQP nano-adjuvant greatly promoted the expression and secretion of cytokines and chemokines with a balance Th1/Th2 immune response
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.